Evaluation of recombinant hirudin (CGP 39393/™REVASC) in the prevention of restenosis after percutaneous transluminal coronary angioplasty. Rationale and design of the HELVETICA trial, a multicentre randomised double blind heparin controlled study - Herrmann, J PR; Simon, R; Umans, V AWN; Peerboom, P F; Keane, D; Runierse, J JMM; Bach, D; Kobi, P; Kerry, R; Close, P; Deckers, J W; Serruys, P W (European Heart Journal, 1995)
Suppl. L